MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

AG14361

CAS No. : 328543-09-5

MCE 国际站：AG14361

产品活性：AG14361 是一种有效的 PARP-1 抑制剂，K_i 值 < 5 nM，在通透的 SW620 细胞和完整的 SW620 细胞中，抑制 PARP-1 的活性，IC₅₀ 值分别为 29 nM 和 14 nM。

研究领域：Cell Cycle/DNA Damage  |  Epigenetics

作用靶点：PARP

In Vitro: AG14361 is a potent PARP-1 inhibitor, with a K_i of < 5 nM, and in permeabilized SW620 and intact SW620 cells, the IC₅₀s are 29 nM and 14 nM, respectively. AG14361 inhibits the proliferation of human cancer cells, such as A549, LoVo, and SW620 cells, with GI₅₀s of 14 μM, 11.2 μM and 20 μM, respectively. Furthermore, AG14361 in combination with NSC 362856 markedly reduces the GI₅₀ value of NSC 362856 in LoVo and A549 cells, but does not exert such an effect in SW620 cells. AG14361 suppresses breast cancer cells with IC₅₀s of 17 μM and 25 μM for 92 J-wt-BRCA1 and 92 J-sh-BRCA1 cells, respectively. AG14361 induces caspase 3/7 activation and cell cycle abnormalities, and also inhibits NF-κB signaling. AG14361 (0.4 μM) enhances the growth-inhibitory and cytotoxic effects of topoisomerase I poisons, with no obvious effect on the formation and reversal of cleavable complexes, and increases the persistence of camptothecin-induced DNA single-strand breaks.

In Vivo: AG14361 (5 and 15 mg/kg, i.p.) has no toxicity and does not inhibit the growth of tumor. However, AG14361 markedly enhances NSC 362856 activity against LoVo xenografts and delays tumor growth when combined with NSC 362856. AG14361 (15 mg/kg, i.p.) treatment before irradiation dramaticly increases the sensitivity to radiation therapy of mice bearing LoVo xenografts. AG14361 (30 mg/kg) synergizes Lestaurtinib (HY-50867) activity on inhibiting breast cancer tumors in allografts.

相关产品：Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  Epigenetics Compound Library  |  Anti-Cancer Compound Library  |  Anti-Aging Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Highly Selective Inhibitors Library  |  iRucaparib-AP6  |  Rucaparib monocamsylate  |  AZD-2461  |  RBN-2397  |  Rucaparib acetate  |  Niraparib tosylate  |  Olaparib-d₈  |  G007-LK  |  Basroparib  |  Anticancer agent 64  |  UPF 1069  |  Talazoparib tosylate  |  BPA-B9  |  MSC2504877  |  Oxychlororaphine  |  PROTAC PARP1 degrader  |  5,7-Dihydroxychromone  |  PARP1-IN-5  |  OUL232  |  Stenoparib  |  PI-1840  |  PARP1-IN-11  |  3-Aminobenzamide  |  PARP1-IN-6  |  OM-153  |  BRCA1-IN-2  |  PARP-2-IN-1  |  JQAD1  |  Dehydrocorydaline (hydroxyl)

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。